Comment on: Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta‐analysis
Special Care in Dentistry · 2024
DOI: 10.1111/scd.12909 ↗At a glance
Leserbrief in Special Care in Dentistry, 2024. Written by Efsun Somay. Institution: Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Baskent University, Ankara, Turkey. Major MEDLINE topics: Bisphosphonate-Associated Osteonecrosis of the Jaw, Bone Density Conservation Agents, Denosumab, Diphosphonates. 5 references.
Abstract (original language)
The assessment conducted by Zhang and colleagues in their systematic review and meta-analysis deserves commendation for its thorough evaluation of the incidence of osteonecrosis of the jaw (ONJ) caused by bisphosphonates and denosumab when used as adjuvant therapy or for controlling bone cancer metastasis.1 The meta-analysis incorporated a cumulative total of 23 prospective studies, which encompassed a patient cohort of 42,003 individuals. The study assessed the primary endpoint in a cohort of 32,815 patients, among whom 616 (2.08%) were diagnosed with ONJ after receiving treatment with either denosumab or bisphosphonates. Patients treated with denosumab had a higher incidence rate of ONJ (RR 1.64, 95% CI 1.10−2.44; p < .05) compared to those treated with bisphosphonates. The authors compared the risk ratio of osteonecrosis of the jaw caused by denosumab and zoledronic acid, given that zoledronic acid was the most commonly used bisphosphonate. The results showed that patients treated with denosumab had a higher incidence rate of ONJ than those treated with zoledronic acid (RR 1.49, 95% CI 0.99−2.25; p < .05). The analysis of subgroups revealed that patients with prostate cancer who were administered denosumab or zoledronic acid had the highest incidences of ONJ, which were 5.0% and 3.0%, respectively. The authors also emphasized that the occurrence of ONJ varied depending on the dosage administered. The authors concluded from the findings that the occurrence of ONJ resulting from the administration of denosumab and bisphosphonates is infrequent and suggested that the judicious use of these drugs could enhance the patient's quality of life. While the study has made significant contributions to the dentistry and oncology literature, I have some concerns regarding the study outcomes and the conclusions drawn by the authors. Several studies have shown that there is a correlation between an increased risk of ONJ caused by bisphosphonates and denosumab and various factors such as tooth extraction and dental implant placement procedures, dental-periodontal or peri-implant infections, trauma related to dentures, bone exostosis, and concurrent usage of chemotherapy and corticosteroids with bisphosphonate.2, 3 Furthermore, although debatable, it has been reported that bone exposure, which typically occurs during dentoalveolar surgery such as tooth extraction, is a triggering factor in approximately 60% of ONJ cases.4 As an illustration, the projected likelihood of ONJ after a dental extraction varies between 0.5% and 14.8% among cancer patients who have undergone bisphosphonate treatment, contingent upon the method of drug delivery.5 Unfortunately, Zhang et al. did not provide details regarding the spontaneous occurrence of ONJ cases or any invasive dental procedures, such as tooth extraction, dental implant placement, or mandibular surgery, that may have preceded the emergence of the condition.1 Nevertheless, it is imperative to consider that invasive procedures that result in bone injury should be circumvented whenever feasible due to the heightened likelihood of ONJ following a tooth extraction or other invasive procedures, particularly in individuals undergoing monthly antiresorptive therapy.4 Therefore, it is reasonable to consider the possibility of the existence of a specific cohort of patients in this meta-analysis who may have demonstrated a heightened vulnerability to ONJ, exceeding the incidence rates reported by Zhang et al.1 In conclusion, I believe that the provision of comprehensive data could augment our understanding of the risk factors associated with ONJ, which in turn may lead to a more cautious administration of antiresorptive agents in patients who have a heightened susceptibility to ONJ following such treatments. The author declares no conflict of interest.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Baskent University, Ankara, Turkey.
ORCID profiles: Efsun Somay
Cite
APA
Somay, E. (2024). Comment on: Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta‐analysis. Special Care in Dentistry. https://doi.org/10.1111/scd.12909
Vancouver
Somay E. Comment on: Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta‐analysis. Special Care in Dentistry. 2024. doi:10.1111/scd.12909
BibTeX
@article{Somay2024,
author = {Somay, Efsun},
title = {Comment on: Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta‐analysis},
journal = {Special Care in Dentistry},
year = {2024},
doi = {10.1111/scd.12909}
}
EUVIMED